Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Sebastian Palmqvist(Lund University), Oskar Hansson(Lund University), Susanna Calling(Lund University), Rik Ossenkoppele(University of California, Berkeley), Erik Stomrud(Lund University), Kaj Blennow(Sahlgrenska University Hospital), Pontus Tideman(Lund University), Tim West(Washington University in St. Louis), Ruben Smith(Lund University), Joel B. Braunstein(C2N Diagnostics (United States)), Niklas Mattsson(Lund University), Gemma Salvadó(Lund University), Shorena Janelidze(Lund University), Philip B. Verghese(Hope Center for Neurological Disorders), Suzanne E. Schindler(Washington University in St. Louis), Mark Monane(C2N Diagnostics (United States))
Cited by 317
Related Papers
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
|The Lancet Neurology|2020|1.3k
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
|Brain|2016|1.2k
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
|Nature Communications|2017|927